20-Deoxyingenol 是一种从Euphorbia kansui的根中分离出的二萜。20-Deoxyingenol 可通过促进体外转录因子 EB (TFEB) 的核易位来促进自噬和溶酶体生物发生。20-Deoxyingenol 可用于骨关节炎 (OA) 的研究。
| 生物活性 | 20-Deoxyingenol, a diterpene, is isolated from the roots ofEuphorbia kansui. 20-Deoxyingenol can promoteautophagyand lysosomal biogenesis by promoting the nuclear translocation of transcription factor EB (TFEB) in vitro. 20-Deoxyingenol can be used for the research of osteoarthritis (OA)[1][2]. |
体外研究
(In Vitro) | 20-Deoxyingenol (2.5-10 mM; 24 h) protects chondrocytes against Tert-butyl hydroperoxide solution (TBHP; 100 μM)-induced cell death[2].
20-Deoxyingenol (5-10 mM) decreases the TBHP-induced upregulation of apoptosis protein cleaved-caspase3 and the senescence protein p16INK4a in chondrocytes[2].
20-Deoxyingenol (2.5-40 mM; 24 h) has no cytotoxic effect on chondrocytes at the concentration less than 10 mM[2].
20-Deoxyingenol (10 mM; 24 h) restores autophagy flux in TBHP treated chondrocytes[2].
20-Deoxyingenol (4-10 mM; 24 h) promotes the nuclear level of TFEB in TBHP treated chondrocytes[2].
|
体内研究
(In Vivo) | 20-Deoxyingenol (20 mg/kg/d; i.p. for 8 weeks) alleviates the progression of OA in the DMM model in mice[2].
| Animal Model: | 10-week-old C57BL/6 male wild-type (WT) mice with destabilization of the medial meniscus (DMM)[2] | | Dosage: | 20 mg/kg | | Administration: | I.p. one time per day, for eight consecutive weeks | | Result: | Had a slightly wider joint space and reduced bone density and calcification compared with the DMM group.
Inhibited the decrease in the thickness of hyaline cartilage (HC), and alleviated the disorder and hypertrophy of chondrocytes in the joint tissues of mice after DMM surgery.
Had less erosion on the surface of the articular cartilage and more proteoglycan content.
Had more positive staining points of LAMP1 and LC3 II, and less cleaved-caspase3 and P16INK4a.
Increased the nuclear level of TFEB. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 结构分类 | |
| 来源 | - Plants
- Euphorbiaceae
- Euphorbia kansuiT. N. Liou ex S. B. Ho
|
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 50 mg/mL(150.41 mM;Need ultrasonic) 配制储备液 | 1 mM | 3.0082 mL | 15.0408 mL | 30.0815 mL | | 5 mM | 0.6016 mL | 3.0082 mL | 6.0163 mL | | 10 mM | 0.3008 mL | 1.5041 mL | 3.0082 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: 2.5 mg/mL (7.52 mM); Suspended solution; Need ultrasonic
此方案可获得 2.5 mg/mL (7.52 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: 2.5 mg/mL (7.52 mM); Suspended solution; Need ultrasonic
此方案可获得 2.5 mg/mL (7.52 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 3. 请依序添加每种溶剂： 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (7.52 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (7.52 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
m.cnreagent.com